Free Trial
NASDAQ:AMGN

Amgen (AMGN) Stock Price, News & Analysis

$311.46
+0.58 (+0.19%)
(As of 07/8/2024 ET)
Today's Range
$310.61
$315.48
50-Day Range
$273.94
$319.31
52-Week Range
$218.61
$329.72
Volume
1.17 million shs
Average Volume
2.74 million shs
Market Capitalization
$167.08 billion
P/E Ratio
44.49
Dividend Yield
2.89%
Price Target
$307.35

Amgen MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.52 Rating Score
Upside/​Downside
1.3% Downside
$307.35 Price Target
Short Interest
Healthy
1.70% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.42
Upright™ Environmental Score
News Sentiment
1.40mentions of Amgen in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$662,812 Sold Last Quarter
Proj. Earnings Growth
5.55%
From $19.47 to $20.55 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.58 out of 5 stars

Medical Sector

70th out of 876 stocks

Biological Products, Except Diagnostic Industry

8th out of 149 stocks

AMGN stock logo

About Amgen Stock (NASDAQ:AMGN)

Amgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.

Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.

Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.

Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.

In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.

Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.

AMGN Stock Price History

AMGN Stock News Headlines

Amgen sign at biopharmaceutical company office
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex (AMGN)
The biotech sector (IBB) is trading just 3% away from its 52-week high and a significant resistance level, suggesting a potential breakout.
mobile phone screen with logo lettering of moderna pharma, stock market chart background
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines (AMGN)
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA
The only way to play the AI boom?
A new AI profit window is opening. But I believe if you want to take advantage of this next wave of AI … You have to do something very few people will have the courage to do.
The 3 Best Healthcare Stocks to Buy in July 2024
The only way to play the AI boom?
A new AI profit window is opening. But I believe if you want to take advantage of this next wave of AI … You have to do something very few people will have the courage to do.
Amgen: You Haven't Seen Anything Yet
3 Stocks to Buy as Ozempic Surges in Popularity
See More Headlines
Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/02/2024
Ex-Dividend for 6/7 Dividend
5/16/2024
Dividend Payable
6/07/2024
Today
7/08/2024
Next Earnings (Confirmed)
8/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AMGN
CUSIP
03116210
Employees
26,700
Year Founded
1980

Price Target and Rating

Average Stock Price Target
$307.35
High Stock Price Target
$360.00
Low Stock Price Target
$200.00
Potential Upside/Downside
-1.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.52
Research Coverage
21 Analysts

Profitability

Net Income
$6.72 billion
Pretax Margin
14.71%

Debt

Sales & Book Value

Annual Sales
$28.19 billion
Cash Flow
$26.39 per share
Book Value
$11.65 per share

Miscellaneous

Free Float
532,734,000
Market Cap
$167.08 billion
Optionable
Optionable
Beta
0.58

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Should I Buy Amgen Stock? AMGN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Amgen Inc.:

  • Amgen's recent earnings report exceeded analysts' expectations, with a higher EPS of $3.96 compared to the consensus estimate of $3.76, indicating strong financial performance.
  • Multiple analyst upgrades and target price increases suggest positive sentiment towards Amgen's stock, potentially leading to price appreciation.
  • Amgen's current stock price of $310.88 on July 5th, 2024, is showing an upward trend, indicating potential growth opportunities.
  • Strong institutional investor interest in Amgen, with notable firms increasing their stakes in the company, signaling confidence in its future prospects.
  • Amgen's diverse portfolio of human therapeutics and global presence provide a stable revenue stream and growth potential in the biopharmaceutical industry.

Cons

Investors should be bearish about investing in Amgen Inc. for these reasons:

  • Amgen's high debt-to-equity ratio of 11.96 may pose a risk in terms of financial leverage and potential constraints on future growth initiatives.
  • While Amgen's revenue was up 22.0% year-over-year, the company's net margin of 12.74% indicates relatively lower profitability compared to some competitors in the industry.
  • Despite recent positive analyst ratings, the stock's PE ratio of 44.41 and price-to-earnings-growth ratio of 2.79 may suggest that the stock is currently overvalued.
  • Market volatility and regulatory challenges in the biopharmaceutical sector could impact Amgen's stock performance and growth prospects in the future.
  • Amgen's 52-week high of $329.72 may indicate potential resistance levels for further stock price appreciation in the near term.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 7, 2024. Please send any questions or comments about these Amgen pros and cons to contact@marketbeat.com.

AMGN Stock Analysis - Frequently Asked Questions

How have AMGN shares performed this year?

Amgen's stock was trading at $288.02 at the beginning of 2024. Since then, AMGN stock has increased by 8.1% and is now trading at $311.46.
View the best growth stocks for 2024 here
.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) posted its earnings results on Thursday, May, 2nd. The medical research company reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.76 by $0.20. The company's revenue was up 22.0% on a year-over-year basis.
Read the conference call transcript
.

What is Robert A. Bradway's approval rating as Amgen's CEO?

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

Does Amgen have any subsidiaries?

Amgen subsidiaries include these companies: TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and more.

Who are Amgen's major shareholders?

Amgen's top institutional investors include DNB Asset Management AS (0.03%), ST Germain D J Co. Inc. (0.01%), Trust Co. of Toledo NA OH and Birch Capital Management LLC. Insiders that own company stock include Amgen Inc, Murdo Gordon, Jonathan P Graham, Robert Eckert, Nancy A Grygiel, Nancy A Grygiel and R Sanders Williams.
View institutional ownership trends
.

How do I buy shares of Amgen?

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV) and Walt Disney (DIS).

This page (NASDAQ:AMGN) was last updated on 7/9/2024 by MarketBeat.com Staff

From Our Partners